Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE TEN versus MYFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE TEN versus MYFED.
DIMETANE-TEN vs MYFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-Ten is a combination of brompheniramine (antihistamine) and phenylephrine (decongestant). Brompheniramine competitively blocks histamine H1 receptors, reducing allergic symptoms; phenylephrine acts as an α1-adrenergic receptor agonist, causing vasoconstriction in nasal mucosa.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
One tablet (chlorpheniramine maleate 4 mg, phenylephrine HCl 10 mg, methscopolamine nitrate 2.5 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
500 mg orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinical context: allows twice-daily dosing; prolonged in renal impairment.
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; remainder as minor pathways.
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant